Skip to main content

Advertisement

Table 4 Microbiologic Response for Common Respiratory Pathogens at Test-of-Cure Visit in the ME Population

From: Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

  Tigecycline Levofloxacin
Isolate n/N % (95% CI) n/N % (95% CI)
Streptococcus pneumoniae 46/50 92.0 (80.8, 97.8) 32/36 88.9 (73.9, 96.9)
Penicillin-intermediate S. pneumoniae 3/3 100 (29.2,100) 5/5 100 (47.8, 100)
Penicillin-resistant S. pneumoniae 2/2 100 (15.8, 100) 3/3 100 (29.2, 100)
Haemophilus influenzae 8/11 72.7 (39.0, 94.0) 6/7 85.7 (42.1, 99.6)
Haemophilus parainfluenzae 5/5 100 (47.8, 100) 9/9 100 (66.4, 100)
Klebsiella pneumoniae 4/4 100 (39.8, 100) 7/7 100 (59.0, 100)
Staphylococcus aureus (all non-MRSA) 7/9 77.8 (40.0, 97.2) 6/6 100 (54.1, 100)
Chlamydia pneumoniae 5/5 100 (47.8, 100) 11/11 100 (71.5, 100)
Mycoplasma pneumoniae 24/25 96.0 (79.6, 99.9) 22/24 91.7 (73.0, 99.0)
Legionella pneumophila 3/3 100 (29.2, 100) 5/5 100 (47.8, 100)
  1. MRSA: methicillin-resistant Staphylococcus aureus